An agreement was reached with New York, 37 other states and the District of Columbia to settle allegations that Shire and Advanced BioHealing illegally promoted Dermagraft, a bioengineered human skin substitute made from cells derived from newborn foreskin tissue for treating diabetic foot ulcers, according to an article in Market Watch.
The settlement will resolve allegations that Shire's marketing of Dermagraft resulted in false claims being submitted to government health care programs -- $14.5 million of the total fee will go to Medicaid, the story said.
Read the Market Watch article